28 Projects

over which proof of concept has been established in either pre-clinical, phase 1 or phase 2 clinical studies.

Established drug formulations with data packages necessary for regulatory applications.

Proof of concept data from pre-clinical and clinical studies supporting the proposed therapeutic applications.

Regulatory filings for multiple drug products.

Granted and pending patents for manufacturing methods, drug formulations and methods of use to treat a range of conditions.

– *Covers the entire drug development process from raw materials to patient dosing.*

Different cannabinoid development strategy than IHL's current programs.

– *Recently completed acquisition of APIRx adds unique cannabinoid formulations and delivery mechanisms protected by patent.*

Clinical Project	Addressable Market Opportunity (in US$)	Stage of Development	Regulatory Stage of Development	Next Steps	Relevant Patents
IHL-42X Obstructive Sleep Apnoea	$10.4B (U.S.)	Phase 2A completed	FDA Pre-IND completed	IND opening study	1x Pending Deemed novel & inventive
IHL-675A Inflammatory Lung Disease	$50.4B (U.S.) by 2022	Pre-clinical completed	FDA Pre-IND completed	Phase 1 CT	2x Pending Deemed novel & inventive
IHL-675A Rheumatoid Arthritis	$57B (U.S.) by 2022	Pre-clinical completed		Phase 1 CT	2x Pending Deemed novel & inventive
IHL-675A Inflammatory Bowel Disease	$20B (U.S.) by 2021	Pre-clinical completed		Phase 1 CT	2x Pending Deemed novel & inventive
IHL-216A TBI/Concussion	$2.9B in 2019	Pre-clinical completed	FDA Pre-IND scheduled (Sept. 2022)	IND opening study	2x Pending Deemed novel & inventive
Psi-GAD Generalized Anxiety Disorder	8M people (U.S. & AUS)	Phase 2A ongoing	FDA Pre-IND completed	Phase 1	Drafting
MedChew™-1401 Pain and Spasticity in Multiple Sclerosis	$62B (Global) in 2021 (a)	Pre-clinical	Pre-IND completed in NL and Switzerland	Phase 1	Granted
MedChew™ GB Post-herpatic Neuralgia	$3.7B (U.S.) by 2027 (n)	Pre-clinical	FDA Pre-IND	Phase 1	Granted
MedChew™-1502 Parkinson's Disease	$8.05B (Global) by 2027; 6.5% CAGR (l)	Pre-clinical	FDA Pre-IND	Phase 1	Granted
MedChew™-1503 Dementia	$23.9B (Global) by 2028; 7.9% CAGR (m)	Pre-clinical	FDA Pre-IND	Phase 1	Granted
MedChew™ RL Restless Legs Syndrome	12.1.% prevalence of U.S. pop. (j)	Pre-clinical	FDA Pre-IND	Phase 1	Granted
MedChew™ Dronabinol Nausea and Vomiting in Chemotherapy	$3.1B (Global) by 2024 (e)	Phase 1A completed	FDA Pre-IND completed	Phase 1B	Granted
APIRx 1505 Flotex Gastro: Chrohn's Disease	$12.6B (Global) by 2024 (k)	Pre-clinical	Pre-regulatory	Phase 1	Drafting

(a) Frost & Sullivan Market Report as commissioned by APIRx, Sept. 2021

(d) Frost & Sullivan Market Report as commissioned by APIRx, Sept. 2021, market opportunity is Irritable Bowel Syndrome / Disease

(e) Healdkeepers, "Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Research Report, History and Forecast 2022-2027", Jan. 2, 2022

(j) Straits Research: Home Care Sleep Screening Devices Market

(k) Heraldkeepers,"Crohn's Disease Drugs Market Research Report 2022: Prospects, Trends Analysis, Market Size and Forecasts to 2027", Jan. 2, 2022

(l) Global Market Insights,"Parkinson's Disease Therapeutics Market", Base Year 2020

(m) Accurize Market Research,"Dementia Drugs Treatment Market", Nov. 27, 2021

(n) Comserve,"U.S. Shingles Vaccine Market", Jan. 4, 2022

(r) Coherent Market Insights "Inflammatory Bowel Disease Market Analysis", Sept. 2021.

Clinical Project	Addressable Market Opportunity (in US$)	Stage of Development	Regulatory Stage of Development	Next Steps	Relevant Patents
CanChew Plus Gastro: IBS	$40B (U.S.) in 2021 (d)	Phase 2A Completed	Pre-IND, ethical approval	Phase 2B	Granted
CanChew RX Gastro: IBD	$2.78B (U.S.) by 2028 (r)	Pre-clinical	Pre-regulatory	Phase 1	Granted
SuppoCan (Suppository) Gastro: IBD	$2.78B (U.S.) by 2028 (r)	Pre-clinical	Pre-regulatory	Phase 1	Granted
Oraximax Gingivitis and Periodontitis	$42B (U.S. and Europe) in 2021 (a)	Clinical Stage	510(k) pre-market submission to FDA	Phase 2	Granted
CheWell Addiction: Cannabis Dependence	$64B (U.S.) in 2021 (c)	Pre-clinical	Pre-IND ready for submission	Phase 1	Drafting
CanQuit Addiction: Tobacco Smoking Cessation	$47.75B (Global) by 2024, 17.3% CAGR (o)	Pre-clinical	Pre-regulatory	Phase 1	Granted
CanQuit O Addiction: Opioid Addiction	$64B (U.S.) in 2021 (c)	Pre-clinical	Pre-regulatory	Phase 1	Granted
APIRx-1601 Skin: Vitiligo	$0.1B (Global) in 2021 (b)	Phase 2 completed	Pre-IND drafting	Phase 1	2x Granted, 1x Pending
APIRx-1602 Skin: Psoriasis	$0.5B (Global) in 2021 (b)	Phase 2A completed	Pre-IND drafting	Phase 1	2x Granted, 1x Pending
APIRx-1603 Skin: Atopic Dermatitis	$1.1B (Global) in 2021 (b)	Phase 2A completed	Pre-IND drafting	Phase 1	2x Granted, 1x Pending
APIRx-1701 Opth: Glaucoma	$10.4B (Global) by2026, 6.3% CAGR (g)	Pre-clinical	Pre-regulatory	in vitro studies	Granted
APIRx-1702 Opth: Dry Eye Syndrome	$6.6B (Global) by 2027, 6.4% CAGR (p)	Pre-clinical	Pre-regulatory	in vitro studies	Granted
APIRx-1801 Ultrapure THC	$31.5B (Global) by 2030; 18.6% CAGR (q)	Developed			Granted
APIRx-1802 Ultrapure CBD	$31.5B (Global) by 2030; 18.6% CAGR (q)	Developed			Granted
APIRx-1803 Ultrapure CBG	$31.5B (Global) by 2030; 18.6% CAGR (q)	Developed			Granted

(b) Frost & Sullivan Market Report as commissioned by APIRx, Sept. 2021, market opportunity is medications and other, where other includes visits to physicians, in/out patient costs

(c) Frost & Sullivan Market Report as commissioned by APIRx, Sept. 2021, market opportunity is Adolescent Substance Abuse

(g) ResearchandMarkets, "Outlook on the Glaucoma Therapeutics Global Market", 2020-2026", Oct. 22. 2021

(o) Worldwide Market Reports,"Smoking Cessation and Nicotine De-Addiction Products Market", May 2018

(p) Future Market Insights,"Dry Eye Syndrome Treatment Market", July 2017

(q) Precedence Research "Cannabis Extract Market", Mar. 2020; includes THC, CBD, CBG and other